Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

RecruitingOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

July 15, 2022

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2028

Conditions
Pleural Effusion, MalignantAscites, MalignantCarcinomaCarcinoma, HepatocellularCarcinoma, Renal CellCarcinoma, RenalCarcinoma, Small CellCarcinoma, Non-Small-Cell LungCarcinoma, Pancreatic DuctalCarcinoma, NeuroendocrineCarcinoma, ThymicCarcinoma, PancreaticCarcinoma BreastCarcinoma, OvarianCarcinoma BladderCarcinoma of Unknown PrimaryCarcinoma of the Head and NeckCarcinoma of the OropharynxCarcinoma of the LarynxCarcinoma of the BladderCarcinoma of EsophagusCarcinoma of the NasopharynxCarcinoma of the PenisCarcinoma of the CervixCarcinoma of the AnusCarcinoma of the VulvaCarcinoma of the AppendixCarcinoma of the Oral CavityCholangiocarcinomaMelanomaMesotheliomaPancreatic Cancer
Trial Locations (1)

94612

RECRUITING

xCures, Oakland

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

xCures

INDUSTRY

lead

Travera Inc

INDUSTRY